Pregnancy: Teratogenic Effects: Pregnancy Category C - Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with Tridesilon (desonide) Cream, %. It is also not known whether Tridesilon (desonide) Cream, % can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Tridesilon (desonide) Cream, % should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Please consult full prescribing information for CLODERM® Cream. Not valid for patients reimbursed by federal health care programs, including Medicare, Medicaid, Tricare, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 . 701 et. seq. state social service block grant programs under 42 . section 1397 et. seq. or any other similar federal or state health care program. Void where prohibited by law, taxed or restricted. Void outside the United States. Void for residents of Massachusetts except for cash-paying patients. The CLODERM® Cream brand offer is void in California, however the generic equivalent offer is valid. Patient is responsible for reporting receipt of card program rewards to any private insurer that pays for or reimburses any part of the prescriptions filled with this card. Void if reproduced. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase or trade, or to counterfeit this card. Offer expires 12 months after initial use . Promius Pharma reserves the right to rescind, revoke or amend this offer at any time without notice.
In controlled clinical trials involving 319 subjects, the incidence of adverse reactions associated with the use of Mometasone Furoate Cream % was %. Reported reactions included burning, pruritus, and skin atrophy. Reports of rosacea associated with the use of Mometasone Furoate Cream % have also been received. In controlled clinical trials (n=74) involving pediatric subjects 2 to 12 years of age, the incidence of adverse experiences associated with the use of Mometasone Furoate Cream % was approximately 7%. Reported reactions included stinging, pruritus, and furunculosis.
The following adverse reactions were reported to be possibly or probably related to treatment with Mometasone Furoate Cream % during clinical trials in 4% of 182 pediatric subjects 6 months to 2 years of age: decreased glucocorticoid levels, 2; paresthesia, 2; folliculitis, 1; moniliasis, 1; bacterial infection, 1; skin depigmentation, 1. The following signs of skin atrophy were also observed among 97 subjects treated with Mometasone Furoate Cream % in a clinical trial: shininess, 4; telangiectasia, 1; loss of elasticity, 4; loss of normal skin markings, 4; thinness, 1; and bruising, 1.